We are live on ! Find out more
DAWN

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

66 hedge funds and large institutions have $430M invested in Day One Biopharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

75% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 12

14% more funds holding

Funds holding: 58 → 66 (+8)

2.92% more ownership

Funds ownership: 66.97% → 69.9% (+2.9%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

38% less capital invested

Capital invested by funds: $698M → $430M (-$269M)

Holders
66
Holders Change
+8
Holders Change %
+13.79%
% of All Funds
1.04%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
18
Increased
21
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
+$14.5M
2
Franklin Resources
Franklin Resources
California
+$7.68M
3
BlackRock
BlackRock
New York
+$5.43M
4
Millennium Management
Millennium Management
New York
+$2.31M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.5M

Top Sellers

Rank Fund Capital Flow
1
RSCM
Rock Springs Capital Management
Maryland
-$6.44M
2
PCM
Pathway Capital Management
California
-$4.08M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.12M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.59M
5
DM
Deerfield Management
New York
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
ALPS Advisors
Colorado
$632K -$106K -7,997 -11%
Two Sigma Investments
27
Two Sigma Investments
New York
$597K +$795K +60,190 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$570K +$334K +25,250 +78%
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$425K +$570K +43,177 New
URS
30
Utah Retirement Systems
Utah
$402K – – –
N
31
Nuveen
North Carolina
$391K +$328K +24,813 +166%
TD Asset Management
32
TD Asset Management
Ontario, Canada
$371K – – –
SRA
33
Summit Rock Advisors
New York
$329K – – –
Goldman Sachs
34
Goldman Sachs
New York
$310K +$88.1K +6,666 +27%
Walleye Capital
35
Walleye Capital
New York
$259K +$345K +26,148 New
State of Tennessee, Department of Treasury
36
State of Tennessee, Department of Treasury
Tennessee
$253K – – –
JP Morgan Chase
37
JP Morgan Chase
New York
$208K -$410K -31,009 -60%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$197K +$263K +19,900 New
New York State Common Retirement Fund
39
New York State Common Retirement Fund
New York
$193K +$149K +11,308 +140%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$193K +$256K +19,408 New
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$185K +$246K +18,604 New
Marshall Wace
42
Marshall Wace
United Kingdom
$176K +$234K +17,743 New
Morgan Stanley
43
Morgan Stanley
New York
$162K +$32.9K +2,489 +18%
MIM
44
MetLife Investment Management
New Jersey
$154K +$206K +15,573 New
PPA
45
Parametric Portfolio Associates
Washington
$149K +$198K +15,016 New
Deutsche Bank
46
Deutsche Bank
Germany
$132K +$86.7K +6,561 +98%
NFGH
47
Nan Fung Group Holdings
Hong Kong
$114K – – –
AIG
48
American International Group
New York
$112K +$71.8K +5,434 +93%
ProShare Advisors
49
ProShare Advisors
Maryland
$106K -$5.97K -452 -4%
Wells Fargo
50
Wells Fargo
California
$99K -$8.61K -652 -6%
1
2
3

DAWN Hedge Fund Activity: Q1 2022 in Review

66 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2022, worth a combined $430M — down 38% from $698M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new DAWN positions and 10 closed out — a net gain of 8 holders — while 21 added to existing stakes and 12 trimmed.

The largest buyer was RA Capital Management, adding an estimated $14.5M. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $6.44M sold.

  • 66 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2022, up from 58 in Q4 2021.
  • Funds reported $430M of Day One Biopharmaceuticals stock for Q1 2022, down 38% quarter-over-quarter.
  • 18 funds opened new Day One Biopharmaceuticals positions in Q1 2022 and 10 closed out, a net change of +8 holders.
  • The largest Day One Biopharmaceuticals buyer in Q1 2022 was RA Capital Management, an estimated $14.5M added.
  • The largest Day One Biopharmaceuticals seller in Q1 2022 was Rock Springs Capital Management, an estimated $6.44M sold.

Based on aggregated 13F filings for Q1 2022.